TABLE 2.
Sensitivity and Specificity for the Serum Lateral Flow Assay with automated read out for diagnosing proven/probable invasive aspergillosis or COVID‐19 associated pulmonary aspergillosis versus no IA in the Overall Study Cohort and Subgroups. Evaluation of Different Optical Density Index (ODI) cut‐offs
| LFA Cut‐off/patient group | 0.5 ODI | 1.0 ODI | ||
|---|---|---|---|---|
| Sensitivity | Specificity | Sensitivity | Specificity | |
| Overall | 79% (22/28) | 80% (70/87) | 50% (14/28) | 97% (84/87) |
| Haematological malignancy | 85% (17/20) | 72% (23/32) | 55% (11/20) | 97% (31/32) |
| Other traditional underlying diseases predisposing for IA but no haematological malignancy | 83% (5/6) | 76% (22/29) | 50% (3/6) | 93% (27/29) |
| COVID‐19 acute respiratory failure but no other underlying disease predisposing for IA | 0% (0/2) | 96% (25/26) | 0% (0/2) | 100% (26/26) |
Abbreviations: COVID‐19, coronavirus disease 2019; IA, invasive aspergillosis; LFA, lateral flow assay; ODI, optical density index.